Group 1 - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 1.60% on September 26, with a trading volume of 6.703 billion yuan [1] - The fund's shares decreased by 25 million, bringing the total shares to 16.407 billion, while the shares increased by 2.655 billion over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 24 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the China Securities Hong Kong Innovative Drug Index (in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its establishment on July 1, 2022, the fund has achieved a return of 46.29%, while the return over the past month is -2.76% [1]
9月26日港股创新药ETF（513120）份额减少2500.00万份
Xin Lang Cai Jing·2025-09-29 01:08